Quality of Life

We prioritize based on the potential to lead to progress on our strategic goals of Earlier Detection, Quality of Life, Better Prevention and Improved Treatment.

See the progress we’ve made in the area of improved treatment:

Reducing Lymphoma Relapse by 34%

Researchers around the world accrued just over 1200 patients to the trial-100 patients came from the Cross Cancer Institute and the Tom Baker Cancer Centre-which allowed the centres to offer state-of-the-art therapy before its available to the general public.

Lymphoma patients in Alberta played a crucial role in improving treatment around the world, answering questions that change the way we treat this disease and getting access to new therapies first, thanks to a groundbreaking clinical trial.

“We were able to offer patients here in Alberta a treatment that wasn’t yet standard of care and were able to learn new things about which treatment was the better one for this particular type of lymphoma,” says Dr. Randeep Sangha, an investigator on the GALLIUM trial and oncologist at the Cross Cancer Institute.

For us to show that this new combination of treatment prolongs progression-free survival bodes well for patients. We want to see if this difference improves even more with longer follow-up.

- Dr. Randeep Sangha

Charting the Best Course for Multiple Myeloma

Because of your investment, this pilot program was leveraged to position Alberta as a lead province in the MCRN Canadian Multiple Myeloma Database initiative that has resonated with Albertans facing multiple myeloma.

Almost 2,900 new cases of multiple myeloma are diagnosed in Canada every year.

A common form of blood cancer generated in the bone marrow, multiple myeloma crowds out healthy ‘plasma cells’ that are used to fight infections. Treatment may involve a stem-cell transplant, and lifelong therapy can have a significant impact on a patient’s quality of life.

On the international spectrum - Canada is punching well above its weight in contributing to multiple myeloma research. The technology isn't fancy - but it will have a lasting impact for Albertans.

- Dr. Christopher Venner

Together we can continue to provide Albertans with the best possible treatment and care available.